DeVita VT Jr., Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68:8643–53.

Article  PubMed  Google Scholar 

Kang E, Kang JH, Koh SJ, Kim YJ, Seo S, Kim JH, Cheon J, Kang EJ, Song EK, Nam EM, et al. Early Integrated Palliative Care in patients with Advanced Cancer: a Randomized Clinical Trial. JAMA Netw Open. 2024;7:e2426304.

Article  PubMed  PubMed Central  Google Scholar 

Greer JA, Applebaum AJ, Jacobsen JC, Temel JS, Jackson VA. Understanding and addressing the role of coping in Palliative Care for patients with Advanced Cancer. J Clin Oncol. 2020;38:915–25.

Article  PubMed  PubMed Central  Google Scholar 

Liu B, Zhou H, Tan L, Siu KTH, Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther. 2024;9:175.

Article  PubMed  PubMed Central  Google Scholar 

André F, Rassy E, Marabelle A, Michiels S, Besse B. Forget lung, breast or prostate cancer: why tumour naming needs to change. Nature. 2024;626:26–9.

Article  PubMed  Google Scholar 

Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807–21.

Article  PubMed  PubMed Central  Google Scholar 

Ledford H. Melanoma drug wins US approval. Nature. 2011;471:561.

Article  PubMed  Google Scholar 

Buonerba C, Ferro M, Di Lorenzo G. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. Expert Rev Anticancer Ther. 2011;11:25–8.

Article  PubMed  Google Scholar 

Foy SP, Jacoby K, Bota DA, Hunter T, Pan Z, Stawiski E, Ma Y, Lu W, Peng S, Wang CL, et al. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature. 2023;615:687–96.

Article  PubMed  Google Scholar 

Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, et al. Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature. 2022;602:503–9.

Article  PubMed  PubMed Central  Google Scholar 

Ramamurthy A, Tommasi A, Saha K. Advances in manufacturing chimeric antigen receptor immune cell therapies. Semin Immunopathol. 2024;46:12.

Article  PubMed  Google Scholar 

Wu J, Wu W, Zhou B, Li B. Chimeric antigen receptor therapy meets mRNA technology. Trends Biotechnol. 2024;42:228–40.

Article  PubMed  Google Scholar 

Keshavarz A, Salehi A, Khosravi S, Shariati Y, Nasrabadi N, Kahrizi MS, Maghsoodi S, Mardi A, Azizi R, Jamali S, Fotovat F. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies. Stem Cell Res Ther. 2022;13:482.

Article  PubMed  PubMed Central  Google Scholar 

Kittai AS, Bond D, Huang Y, Bhat SA, Blyth E, Byrd JC, Chavez JC, Davids MS, Dela Cruz JP, Dowling MR, et al. Anti-CD19 chimeric Antigen receptor T-Cell therapy for Richter Transformation: An International, Multicenter, Retrospective Study. J Clin Oncol. 2024;42:2071–9.

Article  PubMed  Google Scholar 

Parikh RH, Lonial S. Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice. CA Cancer J Clin. 2023;73:275–85.

Article  PubMed  Google Scholar 

Tsiverioti CA, Gottschlich A, Trefny M, Theurich S, Anders HJ, Kroiss M, Kobold S. Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies. Biol Chem. 2024;405:485–515.

Article  PubMed  Google Scholar 

Yang R, Yang Y, Liu R, Wang Y, Yang R, He A. Advances in CAR-NK cell therapy for hematological malignancies. Front Immunol. 2024;15:1414264.

Article  PubMed  PubMed Central  Google Scholar 

Uslu U, Castelli S, June CH. CAR T cell combination therapies to treat cancer. Cancer Cell. 2024;42:1319–25.

Article  PubMed  Google Scholar 

Ebrahimiyan H, Tamimi A, Shokoohian B, Minaei N, Memarnejadian A, Hossein-Khannazer N, Hassan M, Vosough M. Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages. Int Immunopharmacol. 2022;106:108587.

Article  PubMed  Google Scholar 

Chen Y, Yu Z, Tan X, Jiang H, Xu Z, Fang Y, Han D, Hong W, Wei W, Tu J. CAR-macrophage: a new immunotherapy candidate against solid tumors. Biomed Pharmacother. 2021;139:111605.

Article  PubMed  Google Scholar 

Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38:947–53.

Article  PubMed  PubMed Central  Google Scholar 

Xin Q, Chen Y, Sun X, Li R, Wu Y, Huang X. CAR-T therapy for ovarian cancer: recent advances and future directions. Biochem Pharmacol. 2024;226:116349.

Article  PubMed  Google Scholar 

Rosado-Sánchez I, Levings MK. Building a CAR-Treg: going from the basic to the luxury model. Cell Immunol. 2020;358:104220.

Article  PubMed  Google Scholar 

Chang Y, Cai X, Syahirah R, Yao Y, Xu Y, Jin G, Bhute VJ, Torregrosa-Allen S, Elzey BD, Won YY, et al. CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy. Nat Commun. 2023;14:2266.

Article  PubMed  PubMed Central  Google Scholar 

Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, Simon D, Kleyer A, Munoz L, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28:2124–32.

Article  PubMed  Google Scholar 

Dai H, Zhu C, Huai Q, Xu W, Zhu J, Zhang X, Zhang X, Sun B, Xu H, Zheng M, et al. Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models. J Hepatol. 2024;80:913–27.

Article  PubMed  Google Scholar 

Rurik JG, Tombácz I, Yadegari A, Méndez Fernández PO, Shewale SV, Li L, Kimura T, Soliman OY, Papp TE, Tam YK, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375:91–6.

Article  PubMed  PubMed Central  Google Scholar 

Lu J, Jiang G. The journey of CAR-T therapy in hematological malignancies. Mol Cancer. 2022;21:194.

Article  PubMed  PubMed Central  Google Scholar 

Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, Zhang L, Wei G, Tian Y, Zhao K, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature. 2022;609:369–74.

Article  PubMed  PubMed Central  Google Scholar 

Majzner RG, Mackall CL. Tumor Antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8:1219–26.

Article  PubMed  Google Scholar 

Kaczanowska S, Murty T, Alimadadi A, Contreras CF, Duault C, Subrahmanyam PB, Reynolds W, Gutierrez NA, Baskar R, Wu CJ, et al. Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer Cell. 2024;42:35–e5138.

Article  PubMed  Google Scholar 

Zeng W, Zhang P. Resistance and recurrence of malignancies after CAR-T cell therapy. Exp Cell Res. 2022;410:112971.

Article  PubMed  Google Scholar 

Rejeski K, Jain MD, Smith EL. Mechanisms of resistance and treatment of Relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma. Transpl Cell Ther. 2023;29:418–28.

Article  Google Scholar 

Joly E, Hudrisier D. What is trogocytosis and what is its purpose? Nat Immunol. 2003;4:815.

Article  PubMed